PEDIATRIC ONCOLOGY

REFERENCES

• Bennett J. M., Catovsky D., Daniel M. T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Intern. Med. 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Ravindranath Y., Yeager A. M., Chang M. N., et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N. Engl. J. Med. 1996; 334: 1428–1434
   PubMed Web of Science ®Google Scholar
• Smith F. O., Alonzo T. A., Gerbing R. B., Woods W. G., Arceci R. J. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005; 19: 2054–2062
   PubMed Web of Science ®Google Scholar
• Ravindranath Y., Chang M., Steuber C. P., et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005; 19: 2101–2116
   PubMed Web of Science ®Google Scholar
• Larson R. A., Kondo K., Vardiman J. W., et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am. J. Med. 1984; 76: 827–841
   PubMed Web of Science ®Google Scholar
• Acute Myeloid Leukemia. Neoplastic Hematopathology, R Brunning, D. Knowles. Lippincott Williams and Wilkins, Philadelphia 2001; 1667–1715
   Google Scholar
• Tallman M. S., Kwaan H. C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543–553
   PubMed Web of Science ®Google Scholar
• Fenaux P., Chevret S., Guerci A., et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 2000; 14: 1371–1377
   PubMed Web of Science ®Google Scholar
• Mann G., Reinhardt D., Ritter J., et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann. Hematol. 2001; 80: 417–422
   PubMed Web of Science ®Google Scholar
• Burnett A. K., Grimwade D., Solomon E., Wheatley K., Goldstone A H. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all- trans retinoic acid: result of the Randomized MRC. Trial. Blood 1999; 93: 4131–4143
   PubMed Web of Science ®Google Scholar
• Chomienne C., Ballerini P., Balitrand N., et al. All-trans retinoic acid in acute promyelocytic leukemias, II. In vitro studies: structure-function relationship. Blood 1990; 76: 1710–1717
   PubMed Web of Science ®Google Scholar
• Elliott S., Taylor K., White S., et al. Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 1992; 79: 1916–1919
   PubMed Web of Science ®Google Scholar
• Fenaux P., Castaigne S., Dombret H., et al. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992; 80: 2176–2181
   PubMed Web of Science ®Google Scholar
• Testi A. M., Biondi A., Lo C. F., et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106: 447–453
   PubMed Web of Science ®Google Scholar
• Ortega J. J., Madero L., Martin G., et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J. Clin. Oncol. 2005; 23: 7632–7640
   PubMed Web of Science ®Google Scholar
• De Botton S., Coiteux V., Chevret S., et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J. Clin. Oncol. 2004; 22: 1404–1412
   PubMed Web of Science ®Google Scholar
• Thomas X., Le Q. H., Fiere D. Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Ann. Hematol. 2002; 81: 504–507
   PubMed Web of Science ®Google Scholar
• Aldouri M. A., Lopes M. E., Yacoub M., et al. Cardiac transplantation for doxorubicin-induced cardiomyopathy in acute myeloid leukaemia. Br.J Haematol. 1990; 74: 541
   PubMed Web of Science ®Google Scholar
• Niu C., Yan H., Yu T., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94(10)3315–3324
   PubMed Web of Science ®Google Scholar
• Soignet S. L., Maslak P., Wang Z. G., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 1998; 339(19)1341–1348
   PubMed Web of Science ®Google Scholar
• Ghavamzadeh A., Alimoghaddam K., Ghaffari H., et al. [396] Treatment of New Cases of Acute Promyelocytic Leukaemia by Arsenic Trioxide. Blood 2004; 104(11), http://www.abstracts2view.com/hem_sandiego2004/view.php?nu=HEM4L1_2216
   Web of Science ®Google Scholar
• Zhang P. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. J. Biol. Regul. Homeost. Agents. 1999; 13(4)195–200
   PubMed Web of Science ®Google Scholar
• George B., Mathews V., Poonkuzhali B., et al. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia 2004; 18(10)1587–1590
   PubMed Web of Science ®Google Scholar
• Mathews V., George B., Lakshmi K. M., et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107(7)2627–2632
   PubMed Web of Science ®Google Scholar
• Shen Z. X., Shi Z. Z., Fang J., et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2004; 101(15)5328–5335
   PubMed Web of Science ®Google Scholar
• Powell B., Moser B., Stock W., et al. Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. Journal of Clinical Oncology 2007; Vol 25, No. 18S2007 ASCO Annual Meeting Proceedings Part I (June 20 Supplement), 2
   Google Scholar
• Del Toro G., Morris E., Cairo M. S. Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. Clin. Adv. Hematol. Oncol. 2005; 3: 54–61
   PubMedGoogle Scholar
• Jones D. P., Stapleton F. B., Kalwinsky D., McKay C. P., Kellie S. J., Pui C. H. Renal dysfunction and hyperuricemia at presentation and relapse of acute lymphoblastic leukemia. Med. Pediatr. Oncol. 1990; 18: 283–286
   PubMedGoogle Scholar
• Stokes D. N. The tumour lysis syndrome. Intensive care aspects of paediatric oncology. Anaesthesia 1989; 44: 133–136
   PubMed Web of Science ®Google Scholar
• Cohen L. F., Balow J. E., Magrath I. T., Poplack D. G., Ziegler J. L. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am. J. Med. 1980; 68: 486–491
   PubMed Web of Science ®Google Scholar
• Cairo M. S., Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol. 2004; 127: 3–1
   PubMed Web of Science ®Google Scholar
• Howard S. C., Pui C H. Pitfalls in predicting tumor lysis syndrome. Leuk. Lymphoma. 2006; 47: 782–78
   PubMed Web of Science ®Google Scholar
• Oldfield V., Perry C M. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. Drugs 2006; 66: 529–545
   PubMed Web of Science ®Google Scholar
• Jeha S., Kantarjian H., Irwin D., Shen V., Shenoy S., Blaney S, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005; 19: 34–38
   PubMed Web of Science ®Google Scholar
• Cairo M. S. Recombinant Urate Oxidase (Rasburicase): A New Targeted Therapy for Prophylaxis and Treatment of Patients with Hematologic Malignancies at Risk of Tumor Lysis Syndrome. Clin. Lymphoma. 2003; 3: 233–234
   PubMedGoogle Scholar
• Ribeiro R. C., Pui C. H. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin. Lymphoma. 2003; 3: 225–232
   PubMedGoogle Scholar
• Goldman S C. Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert. Rev. Anticancer. Ther. 2003; 3: 429–433
   PubMedGoogle Scholar
• Pui C. H. Rasburicase: a potent uricolytic agent. Expert. Opin. Pharmacother 2002; 3: 433–442
   PubMedGoogle Scholar
• Kornblau S. M., Gandhi V., Andreeff H. M., et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine + cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 1996; 10: 1563–1569
   PubMed Web of Science ®Google Scholar
• Vahdat L, Wong E. T., Wile M. J., et al. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 1994; 84: 3429–3434
   PubMed Web of Science ®Google Scholar
• Warrell R P, Jr., Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986; 4: 74–79
   PubMed Web of Science ®Google Scholar
• Montgomery J. A., Shortnacy-Fowler A. T., Clayton S. D., Riordan J. M., Secrist J A, III. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. J Med Chem 1992; 35: 397–401
   PubMed Web of Science ®Google Scholar
• Zie K. C., Plunkett W. Deoxynucleotide pool deletion and sustained inhibition of ribinucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro–β -D-arabinofuranosyl) adenine. Cancer Res 1996; 56: 3030–3037
   PubMed Web of Science ®Google Scholar
• Parker W. B., Shaddix S. C., Chang C. H., et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibtion of human ribinucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 1991; 34: 2386–2394
   Google Scholar
• Yamauchi T., Nowak B., Keating M. J., Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 3580–3589
   PubMed Web of Science ®Google Scholar
• Lofti K., Mansson E., Spasokoukotskaja T., et al. Biochemical pharmacology and resistance to 2-chloro-2′-deoxyadenosine, a novel analogue of cladribine in human cell lines. Clin Cancer Res 1999; 5: 2438–2444
   PubMed Web of Science ®Google Scholar
• Jeha S., Gandhi V., Chan K. W., et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103: 284–789
   Google Scholar
• Kantarjian H. M., Gandhi V., Kozuch P., et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21: 1167–1173
   PubMed Web of Science ®Google Scholar
• Gandhi V., Kantarjian H., Faderl S., et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemia. Clin Cancer Res 2003; 9: 6335–6342
   PubMed Web of Science ®Google Scholar
• Bonate P., Craig A., Gaynon P., et al. Population pharmacokinetics of clofarabine, a second–generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol 2004; 44: 1309–1322
   PubMed Web of Science ®Google Scholar
• Jeha S., Gaynon P. S., Razzouk B., et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24: 1917–1923
   PubMed Web of Science ®Google Scholar
• Cooper T., Ayres M., Nowak B., et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemotherapy and Pharmacology 2004; 55: 361–368
   PubMed Web of Science ®Google Scholar
• Webber S. A., McCurry K., Zeevi A. Heart and lung transplantation in children. Lancet, 2006; 368: 53–69
   PubMed Web of Science ®Google Scholar
• Green M., Webber S. Posttransplantation lymphoproliferative disorders. Pediatr. Clin. N. Am. 2003; 50: 1471–1491
   PubMed Web of Science ®Google Scholar
• Quintini C., Kato T., Gaynor J. J., et al. Analysis of risk factors for the development of postransplant lymphoproliferative disorder among 119 children who received primary intestinal transplants at a single center. Transplant Proceed 2006; 38: 1755–1758
   PubMed Web of Science ®Google Scholar
• Buell J. F., Gross T. G., Woodle E. S. Malignancy after transplantation. Transplantation 2005; 80: S254–S264
   PubMed Web of Science ®Google Scholar
• Carton G., Blasco H., Paintaud G., et al. Pharmakokinetics of rituximab and its clinical use: Thoughts for the best use?. Crit. Rev. in Oncol/Hematol 2007; 62: 43–52
   PubMed Web of Science ®Google Scholar
• Tsutumy Y., Kanamori H., Mori A. Reactivation of hepatitis B virus with rituximab. Expert. Opin. Drug Saf. May, 2005; 4(3)599–608
   PubMedGoogle Scholar
• Freim Wahl F. G., Folvik M. R., Torp S. H. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: a case report and review of the literature. Clin Neuropathol 2007; 26: 68–73
   PubMed Web of Science ®Google Scholar
• Webber S., Harmon W., Faro A., et al. Anti-CD20 monoclonal antibody (rituximab) for refractory PTLD after pediatric solid organ transplantation: multicenter experience from a registry and from a prospective clinical trial. Blood 2004; 104, (ASH Meeting Abstracts) Abstract 746
   Google Scholar
• Gross T. G., Bucuvals J. C., Park J. R., et al. Low-dose Chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in Children after solid organ transplantion. J. Clin. Oncol. 2005; 23: 6481–6488
   PubMed Web of Science ®Google Scholar
• Orjuela M., Gross T. G., Cheung Y. K., et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplantation lymphoproliferative disorder following solid organ transplantation. Clin. Cancer Res. 2003; 9: 3945s–3952s, (suppl.)
   PubMed Web of Science ®Google Scholar